PMC:7558914 / 466-1047 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"39","span":{"begin":434,"end":442},"obj":"Species"},{"id":"43","span":{"begin":156,"end":174},"obj":"Chemical"},{"id":"44","span":{"begin":313,"end":331},"obj":"Chemical"},{"id":"45","span":{"begin":337,"end":349},"obj":"Chemical"},{"id":"46","span":{"begin":353,"end":372},"obj":"Chemical"},{"id":"47","span":{"begin":524,"end":542},"obj":"Chemical"},{"id":"48","span":{"begin":548,"end":560},"obj":"Chemical"},{"id":"66","span":{"begin":248,"end":267},"obj":"Disease"},{"id":"67","span":{"begin":466,"end":476},"obj":"Disease"}],"attributes":[{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D006886"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D006886"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D017963"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C558899"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D006886"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D017963"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:D012140"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"tment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respiratory illness with clinical risk factors (33.3%). Combined hydroxychloroquine with azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxych"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":248,"end":267},"obj":"Phenotype"},{"id":"T2","span":{"begin":466,"end":476},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"tment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respiratory illness with clinical risk factors (33.3%). Combined hydroxychloroquine with azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxych"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":92,"end":155},"obj":"Sentence"},{"id":"T7","span":{"begin":156,"end":303},"obj":"Sentence"},{"id":"T8","span":{"begin":304,"end":403},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"tment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respiratory illness with clinical risk factors (33.3%). Combined hydroxychloroquine with azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxych"}